← Leaderboards
Chao-Yie Yang
University Of Tennessee Health Sci Ctr
$1,973,845
Attributed
$3,947,689
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $865.4K · FY2013–23$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$3,947,689 · 3
By mechanism
R01$3,536,999 · 2
R21$410,690 · 1
Top collaborators
- Sophie Paczesny7 shared
- Valeria Visconte2 shared
Most similar at University Of Tennessee Health Sci Ctr
Same institution · by research overlap
- Ae-Kyung Yi$4,246,183
- Valeria Visconte$205,345
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoLeadToxic EffectTherapeutic DevelopmentProteinsDrug TargetingStructureTherapeutic TargetExhibitsIn VitroMalignant NeoplasmsInnovationBaseAnimal ModelLifeLigandsHematopoieticCellsBloodHeart FailureHigh Throughput ScreeningAllogenicBiological MarkersFoundations
Grant awards (9)
Targeting defective spliceosomal pathway in myeloid malignancies$178,991
R21 · FY2023 · CA · contact PI
Development of first-in-class ST2 inhibitors for treating graft-versus-host disease$633,696
R01 · FY2022 · HL · contact PI
Targeting defective spliceosomal pathway in myeloid malignancies$231,699
R21 · FY2022 · CA · contact PI
Development of first-in-class ST2 inhibitors for treating graft-versus-host disease$636,111
R01 · FY2021 · HL · contact PI
Development of first-in-class ST2 inhibitors for treating graft-versus-host disease$650,311
R01 · FY2020 · HL · contact PI
Development of first-in-class ST2 inhibitors for treating graft-versus-host disease$641,835
R01 · FY2019 · HL · contact PI
High Throughput Screening (HTS) to Discover Graft-Versus-Host Disease Inhibitors$323,596
R01 · FY2015 · CA
High Throughput Screening (HTS) to Discover Graft-Versus-Host Disease Inhibitors$313,891
R01 · FY2014 · CA
High Throughput Screening (HTS) to Discover Graft-Versus-Host Disease Inhibitors$337,559
R01 · FY2013 · CA